Diabetes patients can be a target for chronic kidney disease but can also take aim back: This is the message from AstraZeneca’s new Farxiga TV ad, which is pushing the drug’s new CKD label. There is ...
Type 2 diabetes is the most common form of diabetes. It can be diagnosed at any age and increases your risk of several other health problems. Farxiga (far-see-guh) is just one of the many prescription ...
Treatment with dapagliflozin led to a statistically significant improvement in HbA1c compared with placebo. The Food and Drug Administration (FDA) has expanded the approval of Farxiga ® (dapagliflozin ...
The SGLT2 inhibitor medicines have changed how heart failure is managed. Originally sodium-glucose cotransporter 2 (SGLT2) inhibitors were used to lower blood sugar levels in people who have type 2 ...
WILMINGTON, Del.--(BUSINESS WIRE)--High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a statistically significant and clinically meaningful ...
Indication: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The FDA has approved Farxiga (dapagliflozin) to reduce the risk of cardiovascular ...
Both Farxiga (dapagliflozin) and Jardiance (empagliflozin) help manage blood sugar levels in adults and some children with type 2 diabetes. They also reduce risks associated with chronic kidney ...
Phase III DAPA-MI trial will evaluate FARXIGA as a treatment to reduce mortality and the risk of heart failure following a heart attack WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca has been granted ...
Results from the DELIVER and DAPA-HF Phase III trials demonstrate FARXIGA’s efficacy in heart failure regardless of ejection fraction WILMINGTON, Del.--(BUSINESS WIRE)-- High-level results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback